查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870203

同種異體幹細胞市場按組織類型、應用、來源、產品類型、最終用戶和分銷管道分類－2025-2032年全球預測

Allogeneic Stem Cells Market by Tissue Type, Application, Source, Product Type, End-User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，異體幹細胞市場將成長至 13.6539 億美元，複合年成長率為 19.49%。

關鍵市場統計數據
基準年 2024 3.2834億美元
預計年份：2025年 3.9314億美元
預測年份 2032 1,365,390,000 美元
複合年成長率 (%) 19.49%

重點介紹異體幹細胞領域，為領導者提供臨床潛力、生產現狀和策略決策工具的架構。

利用供體來源細胞治療多種疾病的異體幹細胞療法，已從概念階段發展成為具體的臨床應用。細胞取得、免疫調節和可擴展生產技術的進步，以及監管途徑的不斷完善，重新激發了生物製藥、契約製造和臨床服務供應商的關注。與自體療法相比，這些治療方法具有顯著優勢，包括即用型、標準化劑量以及規模經濟效益，從而降低了治療方案的複雜性。

揭示同種異體細胞治療中重塑臨床路徑、生產模式和商業化策略的變革性變化

異體幹細胞領域正經歷多重同步變革，重新定義價值創造與競爭優勢。在臨床方面，多重治療和聯合療法正在拓展供體來源細胞的治療效用，而免疫工程和標靶遞送技術則在提升安全性和有效性。與臨床發展同步，法規環境也在日趨成熟，監管機構正不斷完善關於療效、可比較性和上市後監測的指導方針，以降低研發者的不確定性，並加速專案風險規避。

評估美國2025年宣布的關稅調整對供應鏈、籌資策略和臨床項目成本的累積影響

2025年的關稅調整為異體幹細胞研發企業及其生產合作夥伴的全球物流和採購計算帶來了新的複雜性。關稅帶來的成本壓力主要影響進口耗材、特殊試劑以及細胞處理和低溫儲存所需的某些設備，迫使各機構重新評估其供應商組合，並在條件允許的情況下考慮區域化籌資策略。這些變化使得供應鏈韌性成為經營團隊的首要任務，因為延誤和對單一供應商的依賴可能會擾亂臨床試驗的進度，並影響患者的治療。

提取組織類型、治療用途、原料來源、產品形式、最終用戶和配銷通路等方面的細緻細分資訊，以指導產品組合優先級排序。

有效的細分框架能夠辨識技術風險、臨床機會和商業性適用性三者之間的交集。組織類型區分體現在造血幹細胞和間質幹細胞之間。造血幹細胞通常從骨髓或周邊血液中收集，用於血液學和免疫相關疾病的治療；而間質間質幹細胞，常因其免疫調節和再生特性而備受關注。這些組織來源之間的關係會影響捐贈者選擇、生產流程和療效研究設計，因此需要針對每個來源製定相應的開發路徑。

識別美洲、歐洲、中東和非洲以及亞太地區影響同種異體移植療法監管方法、製造地和應用路徑的區域趨勢

區域差異正在影響異體幹細胞療法的推廣速度和結構。在美洲，再生醫學和先進治療方法的法規結構日益強調簡化核准流程，而強大的臨床試驗體系和一體化的醫院系統則支持早期商業性推出和真實世界證據的累積。這種環境有利於那些能夠協調多中心研究並與支付方協商基於療效的合約和醫保覆蓋模式的申辦方。

策略性企業行動與競爭模式塑造同種異體細胞專案研發、生產與物流卓越領導力

在異體幹細胞領域運作的公司可以歸納為幾種不同的類型，這些類型反映了不同的規模化和價值獲取路徑。一種類型是垂直整合的開發商，他們透過整合內部研發、製程開發和臨床試驗，保護智慧財產權並直接控制關鍵品質屬性。另一種類型包括專業的契約製造組織 (CMO) 和服務供應商，他們為多家開發人員提供可擴展的生產能力、法規支援和技術轉移服務，從而加快那些傾向於輕資產商業化模式的客戶的臨床應用進程。

為產業領導者提供切實可行的、優先排序的建議，以增強專案穩健性、供應鏈韌性、監管準備度和市場接受度。

首先，在早期研發決策中就應建構供應鏈韌性，具體措施包括：對關鍵試劑的多個供應商進行資格認證、建立區域採購管道以及維持戰略庫存緩衝，以降低海關和關稅造成的供應中斷風險。早期採用多供應商策略和替代材料策略可以降低單一供應商風險，並提高專案的連續性。其次，投資於模組化和平台化生產方式，以實現快速規模化生產，並靈活地利用通用生產線滿足多種適應症的需求。這有助於提高資本效率，並縮短臨床試驗的前置作業時間。

該報告對用於得出報告結論的跨學科研究方法進行了清晰的描述，該方法結合了原始研究、二手文獻綜述和專家檢驗。

本分析的調查方法結合了與主要相關利益者的對話、有針對性的文獻綜述以及反覆的專家檢驗，以確保獲得平衡且切實可行的見解。主要資訊來源包括對臨床研究人員、生產主管、供應鏈專家和監管顧問的結構化訪談，這些訪談提供了關於營運限制、臨床終點和市場進入趨勢的真實觀點。這些定性見解與來自同行評審文獻、監管指導文件和技術白皮書等二手資訊進行三角驗證，以便更好地理解相關趨勢和技術發展。

簡要概述了為何整合營運效率、有針對性的臨床重點和策略夥伴關係對於實現異體幹細胞治療的潛力至關重要。

異體幹細胞領域正處於轉折點，科學進步和製造創新，加上嚴謹的商業化策略，有望轉化為對患者產生實際影響的療效。僅憑臨床療效並不能保證持續廣泛的應用；成功需要嚴謹的臨床轉化、可重複的生產製造、穩健的供應鏈以及積極的醫保合作。能夠整合這些能力的機構將更有能力應對複雜的監管環境，並縮短從臨床試驗到常規應用的路徑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 學術界與生物製藥公司之間的策略合作加速了異體幹細胞治療的研發進程。
  • 異體幹細胞基因編輯技術在治療遺傳性血液疾病的進展
  • 利用HLA基因敲除技術開發通用供體異體幹細胞，以最大程度地減少免疫排斥反應
  • 引入自動化封閉式製程生產系統以擴大同種異體細胞療法的生產。
  • 將人工智慧應用於同種異體幹細胞株的篩選和品管
  • 源自異體幹細胞平台的現成CAR-T療法的出現，縮短了前置作業時間
  • 監管協調和標準化效力測試，以確保同種異體細胞產品的一致性
  • 拓展冷凍保存和低溫運輸解決方案，以支持現成細胞療法的全球分銷
  • 增加異體間質幹細胞療法在自體免疫和發炎性疾病治療的投資
  • iPS細胞衍生同種異體產品在神經退化性疾病適應症的應用

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依組織類型分類的異體幹細胞市場

  • 造血幹細胞
    • 骨髓
    • 周邊血
  • 間質幹細胞
    • 脂肪組織
    • 骨髓
    • 臍帶

第9章 同種異體幹細胞市場：依應用領域分類

  • 心血管疾病
    • 心肌梗塞
    • 周邊動脈疾病
  • 免疫療法
    • CAR-T療法
    • 樹突細胞療法
    • NK細胞療法
  • 神經系統疾病
    • 阿茲海默症
    • 多發性硬化症
    • 帕金森氏症
    • 脊髓損傷
  • 整形外科
    • 骨再生
    • 軟骨修復
    • 脊椎融合手術
  • 創傷治療
    • 燒傷傷口
    • 慢性傷口
    • 糖尿病足潰瘍

第10章 異體幹細胞市場（依來源分類）

  • 脂肪組織
  • 骨髓
  • 周邊血
  • 臍帶

第11章 依產品類型分類的異體幹細胞市場

  • 冷凍保存
  • 冷凍乾燥
  • 新鮮的

第12章 依最終用戶分類的異體幹細胞市場

  • 契約製造組織
  • 醫院和診所
  • 研究所

第13章 依分銷管道分類的異體幹細胞市場

  • 直銷
  • 經銷商
  • 線上管道

第14章 異體幹細胞市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 依組別分類的異體幹細胞市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國異體幹細胞市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Mesoblast Limited
    • Pluristem Therapeutics, Inc.
    • Athersys, Inc.
    • Gamida Cell Ltd.
    • Cynata Therapeutics Limited
    • Fate Therapeutics, Inc.
    • Allogene Therapeutics, Inc.
    • Celularity, Inc.
    • TiGenix NV
    • Osiris Therapeutics, Inc.
Product Code: MRR-4969A8FF998A

The Allogeneic Stem Cells Market is projected to grow by USD 1,365.39 million at a CAGR of 19.49% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 328.34 million
Estimated Year [2025] USD 393.14 million
Forecast Year [2032] USD 1,365.39 million
CAGR (%) 19.49%

A focused orientation to the allogeneic stem cell landscape that frames clinical promise, manufacturing realities, and strategic decision levers for leaders

Allogeneic stem cell therapies, which leverage donor-derived cells to treat a range of indications, have moved from conceptual promise to tangible clinical momentum. Advances in cell sourcing, immune modulation, and scalable manufacturing have converged with evolving regulatory pathways to create renewed interest across biopharma, contract manufacturing, and clinical service providers. These therapies offer distinct advantages over autologous approaches, including the potential for off-the-shelf availability, standardized dosing, and economies of scale that can reduce per-treatment complexity.

Despite clear clinical opportunities, the pathway to broad adoption demands rigorous attention to supply chain integrity, cryopreservation techniques, and robust quality systems that ensure product consistency across batches and geographies. Stakeholders must reconcile scientific promise with operational realities, including donor screening, potency assays, and cold-chain logistics. As a result, strategic leaders increasingly prioritize investments in process development, modular manufacturing capacity, and regulatory engagement to reduce time-to-clinic and de-risk late-stage programs. The landscape rewards organizations that can align translational science with disciplined commercialization planning and adaptive manufacturing strategies.

Unearthing transformative shifts reshaping clinical pathways, manufacturing models, and commercialization strategies in allogeneic cell therapy

The allogeneic stem cell field is undergoing several concurrent shifts that are redefining value creation and competitive advantage. Clinically, multiplexed approaches and combinatorial regimens are expanding the therapeutic utility of donor-derived cells, with immune engineering and targeted delivery improving safety and efficacy profiles. This clinical evolution is paralleled by regulatory maturation: agencies are clarifying guidance around potency, comparability, and post-market surveillance, which reduces ambiguity for developers and accelerates program de-risking.

Operationally, manufacturing paradigms are shifting from centralized, bespoke facilities to hybrid networks where contract manufacturing organizations, regional centers, and flexible modular platforms coexist. This decentralization improves responsiveness to regional demand and mitigates single-point-of-failure risks in the supply chain. Moreover, improvements in cryopreservation and logistics, along with digital batch record systems and analytics, are raising the bar for reproducibility and lowering manufacturing variance. From a commercial perspective, payers and providers increasingly demand evidence of real-world durability and health-economic benefits, encouraging developers to integrate outcomes measurement into clinical programs early. Together, these shifts reward organizations that adopt end-to-end thinking, build cross-functional capabilities, and partner strategically across development, manufacturing, and care-delivery ecosystems.

Assessing the cumulative implications of United States tariff adjustments announced in 2025 on supply chains, sourcing strategies, and clinical program costs

The tariff adjustments implemented in 2025 have introduced new layers of complexity into the global logistics and sourcing calculus for allogeneic stem cell developers and their manufacturing partners. Tariff-induced cost pressures have primarily affected imported consumables, specialized reagents, and certain instrument categories critical to cell processing and cryogenic storage, prompting organizations to re-evaluate supplier portfolios and consider regionalizing procurement strategies where feasible. These shifts have made supply chain resilience a top boardroom priority, as delays or single-supplier dependencies can disrupt clinical timelines and patient access.

In response, many stakeholders accelerated supplier qualification programs, invested in local sourcing partnerships, and reconfigured inventory strategies to maintain continuity while managing incremental cost impacts. The tariffs also catalyzed conversations about vertical integration for select inputs, particularly where long-term supply certainty materially impacts clinical throughput. Regulatory filings and clinical operations teams have had to factor potential customs-related uncertainties into enrollment and manufacturing windows, and quality assurance functions have increased oversight on incoming material traceability. Overall, the 2025 tariff environment emphasizes the importance of flexible procurement, dual sourcing, and strategic inventory planning to preserve program momentum and protect patient-facing delivery schedules.

Extracting nuanced segmentation intelligence across tissue types, therapeutic applications, source origins, product formats, end-users, and distribution channels to guide portfolio prioritization

An effective segmentation framework illuminates where technical risk, clinical opportunity, and commercial fit intersect. Tissue-type differentiation distinguishes between hematopoietic stem cells, which are commonly derived from bone marrow and peripheral blood and serve hematologic and immune-focused indications, and mesenchymal stem cells, which originate from adipose tissue, bone marrow, and umbilical cord and are often pursued for their immunomodulatory and regenerative properties. These tissue-source relationships influence donor selection, manufacturing flow, and potency assay design, and they therefore deserve tailored development pathways.

Application-level segmentation further clarifies strategic focus areas. Cardiovascular indications such as myocardial infarction and peripheral arterial disease demand delivery systems and endpoints that differ substantially from immunotherapy programs, where CAR-T, dendritic cell, and natural killer cell approaches require specialized cell engineering and manufacturing controls. Neurological targets like Alzheimer's disease, multiple sclerosis, Parkinson's disease, and spinal cord injury create a distinct set of translational and regulatory challenges linked to the blood-brain barrier and long-term outcome measurement. In orthopedics, priorities center on bone regeneration, cartilage repair, and spine fusion, each requiring unique scaffolding and local delivery strategies. Wound healing programs that address burn wounds, chronic wounds, and diabetic foot ulcers emphasize local immunomodulation and matrix remodeling, with value often measured in healing time and functional recovery.

Source-based segmentation underscores that adipose tissue, bone marrow, peripheral blood, and umbilical cord each carry practical implications for donor logistics, cell yield, and regulatory categorization. Product-format segmentation differentiates cryopreserved, freeze-dried, and fresh offerings, with cryopreserved products offering logistical flexibility, freeze-dried approaches promising ambient stability in some emerging modalities, and fresh products necessitating tight coordination between manufacturing and site administration. End-user segmentation highlights differing procurement cycles and quality requirements among contract manufacturing organizations, hospitals and clinics, and research institutes, all of which inform commercial engagement models and service-level commitments. Finally, distribution-channel segmentation-comparing direct sales, distributors, and online channels-determines how value is captured across customer relationships, pricing strategies, and after-sales support. Together, these segmentation lenses enable leaders to prioritize investments that align technical feasibility with commercial pathways and operational capabilities.

Illuminating regional dynamics across the Americas, EMEA, and Asia-Pacific that influence regulatory approaches, manufacturing footprints, and adoption pathways for allogeneic therapies

Regional variation shapes the speed and structure of adoption for allogeneic stem cell therapies. In the Americas, regulatory frameworks increasingly emphasize streamlined pathways for regenerative medicines and advanced therapies, with strong clinical trial ecosystems and integrated hospital systems that can support early commercial launches and real-world evidence generation. These conditions favor sponsors who can coordinate multi-site studies and engage with payers on outcomes-based contracting and coverage models.

Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement landscape where country-level pathways, health technology assessment processes, and decentralized procurement policies require tailored access strategies. Stakeholders must navigate differing standards for manufacturing certification, varying import requirements, and distinct approaches to value assessment. Asia-Pacific encompasses a wide spectrum of markets, from highly regulated jurisdictions with advanced clinical infrastructure to emerging markets that offer faster patient recruitment and cost-efficient manufacturing options. Across these regions, local partnerships and regulatory know-how are essential to bridging clinical evidence generation with market access, while regional manufacturing hubs can reduce logistics friction and support faster rollouts.

Strategic corporate behaviors and competitive archetypes shaping leadership in development, manufacturing, and logistical excellence for allogeneic cell programs

Companies active in the allogeneic stem cell space align into observable archetypes that reflect differing routes to scale and value capture. One archetype consists of vertically integrated developers that combine in-house research, process development, and clinical execution to protect intellectual property and maintain direct control over critical quality attributes. A second archetype includes specialized contract manufacturing organizations and service providers that offer scalable capacity, regulatory support, and technology transfer capabilities to multiple developers, thereby accelerating time-to-clinic for clients that prefer asset-light commercialization.

Other firms focus on supply chain and logistics excellence, building cold-chain networks, cryogenic storage solutions, and tracking systems that reduce loss and improve product viability across distances. Strategic partnerships and alliances are a common growth lever: co-development agreements, equity investments, and manufacturing partnerships help distribute risk and accelerate platform adoption. Competitive differentiation increasingly hinges on demonstrated manufacturing reproducibility, breadth of regulatory experience, and the ability to deliver clinical-grade evidence that supports payer discussions. Investors and corporate development teams prize organizations that can combine technical differentiation with scalable operations and validated route-to-market plans, and successful players tend to balance deep scientific expertise with rigorous process controls and market-oriented commercialization capabilities.

Practical and prioritized recommendations that industry leaders can implement to advance program robustness, supply resilience, regulatory readiness, and market adoption

First, integrate supply chain resilience into early development decisions by qualifying multiple suppliers for critical reagents, establishing regional procurement channels, and maintaining strategic inventory buffers to mitigate customs and tariff interruptions. Early dual sourcing and alternative-material strategies reduce single-provider risk and improve program continuity. Second, invest in modular and platform-based manufacturing approaches that enable rapid scale-up and provide flexibility to serve multiple indications from common production lines, thereby improving capital efficiency and reducing lead times to clinic.

Third, embed health-economic and outcomes evidence generation into clinical development plans from the outset to facilitate payer engagement and reimbursement negotiations. Demonstrating real-world durability and value can accelerate adoption in hospital systems. Fourth, pursue targeted partnerships with contract manufacturers, logistics specialists, and clinical networks that complement internal capabilities and expedite operational readiness. Fifth, prioritize robust analytical development and potency assays that align with regulatory expectations and enable comparability across batches and sites. Finally, cultivate cross-functional regulatory dialogues with authorities early and often to clarify expectations around post-market surveillance, potency metrics, and labeling, which reduces downstream uncertainty and accelerates patient access.

Transparent explanation of the interdisciplinary research approach used to develop the report's insights, combining primary engagement, secondary synthesis, and expert validation

The research methodology underpinning this analysis integrates primary stakeholder engagement, targeted literature synthesis, and iterative expert validation to ensure balanced, actionable findings. Primary inputs included structured interviews with clinical investigators, manufacturing leaders, supply chain specialists, and regulatory advisors, which provided real-world perspectives on operational constraints, clinical endpoints, and market access dynamics. These qualitative insights were triangulated with secondary sources spanning peer-reviewed literature, regulatory guidance documents, and technology white papers to contextualize trends and technical developments.

To enhance rigor, findings were validated through consultations with subject-matter experts and cross-checked against known regulatory milestones and public clinical progress. The methodology emphasized transparency about data provenance and uncertainty, documenting assumptions around supply chain behavior, regulatory interpretation, and clinical translation. Where necessary, sensitivity around proprietary commercial practices was respected, and industry anonymization techniques preserved the integrity of competitive insights while allowing readers to trust the reported strategic implications and operational recommendations.

A concise synthesis highlighting why integrated operational excellence, targeted clinical focus, and strategic partnerships are essential to realizing the potential of allogeneic stem cell therapies

The allogeneic stem cell sector stands at an inflection point where scientific advances and manufacturing innovations can translate into meaningful patient impact if matched with disciplined commercialization strategies. Clinical promise alone does not guarantee sustainable adoption; instead, success requires coupling translational rigor with reproducible manufacturing, resilient supply chains, and proactive payer engagement. Organizations that align these capabilities will be better positioned to navigate regulatory complexity and shorten the path from trial to routine use.

In closing, leaders should view the current environment as an opportunity to build enduring advantage by investing in modular manufacturing, robust analytical frameworks, and strategic partnerships that expand capacity and de-risk program execution. The pathway to commercial success depends on integrated planning across R&D, operations, and market access functions, and the organizations that execute on these coordinated priorities will set the standards for the next wave of allogeneic therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Strategic partnerships between academia and biopharma to accelerate allogeneic stem cell therapy pipelines
  • 5.2. Advancements in gene editing of allogeneic stem cells for treatment of genetic blood disorders
  • 5.3. Development of universal donor allogeneic stem cells through HLA knockout to minimize immune rejection
  • 5.4. Adoption of automated closed process manufacturing systems to scale allogeneic cell therapy production
  • 5.5. Integration of artificial intelligence in selection and quality control of allogeneic stem cell lines
  • 5.6. Emergence of off-the-shelf CAR-T therapies derived from allogeneic stem cell platforms to reduce lead times
  • 5.7. Regulatory harmonization and standardized potency assays to ensure consistency in allogeneic cell products
  • 5.8. Expansion of cryopreservation and cold chain solutions to support global distribution of off-the-shelf cell therapies
  • 5.9. Growing investment in allogeneic mesenchymal stem cell therapies targeting autoimmune and inflammatory diseases
  • 5.10. Application of induced pluripotent stem cell derived allogeneic products in neurodegenerative disease indications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allogeneic Stem Cells Market, by Tissue Type

  • 8.1. Hematopoietic Stem Cells
    • 8.1.1. Bone Marrow
    • 8.1.2. Peripheral Blood
  • 8.2. Mesenchymal Stem Cells
    • 8.2.1. Adipose Tissue
    • 8.2.2. Bone Marrow
    • 8.2.3. Umbilical Cord

9. Allogeneic Stem Cells Market, by Application

  • 9.1. Cardiovascular
    • 9.1.1. Myocardial Infarction
    • 9.1.2. Peripheral Arterial Disease
  • 9.2. Immunotherapy
    • 9.2.1. CAR-T Therapies
    • 9.2.2. Dendritic Cell Therapies
    • 9.2.3. NK Cell Therapies
  • 9.3. Neurological Disorders
    • 9.3.1. Alzheimers Disease
    • 9.3.2. Multiple Sclerosis
    • 9.3.3. Parkinsons Disease
    • 9.3.4. Spinal Cord Injury
  • 9.4. Orthopedics
    • 9.4.1. Bone Regeneration
    • 9.4.2. Cartilage Repair
    • 9.4.3. Spine Fusion
  • 9.5. Wound Healing
    • 9.5.1. Burn Wounds
    • 9.5.2. Chronic Wounds
    • 9.5.3. Diabetic Foot Ulcers

10. Allogeneic Stem Cells Market, by Source

  • 10.1. Adipose Tissue
  • 10.2. Bone Marrow
  • 10.3. Peripheral Blood
  • 10.4. Umbilical Cord

11. Allogeneic Stem Cells Market, by Product Type

  • 11.1. Cryopreserved
  • 11.2. Freeze Dried
  • 11.3. Fresh

12. Allogeneic Stem Cells Market, by End-User

  • 12.1. Contract Manufacturing Organizations
  • 12.2. Hospitals and Clinics
  • 12.3. Research Institutes

13. Allogeneic Stem Cells Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Channels

14. Allogeneic Stem Cells Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Allogeneic Stem Cells Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Allogeneic Stem Cells Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Mesoblast Limited
    • 17.3.2. Pluristem Therapeutics, Inc.
    • 17.3.3. Athersys, Inc.
    • 17.3.4. Gamida Cell Ltd.
    • 17.3.5. Cynata Therapeutics Limited
    • 17.3.6. Fate Therapeutics, Inc.
    • 17.3.7. Allogene Therapeutics, Inc.
    • 17.3.8. Celularity, Inc.
    • 17.3.9. TiGenix N.V.
    • 17.3.10. Osiris Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALLOGENEIC STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)

TABLE